Influenza vaccines: A moving interdisciplinary field

Viruses

Volumn 6, Issue 10, 2014, Pages 3809-3826

  Schotsaert, Michael ^a   García Sastre, Adolfo ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvants; Correlates of protection; Influenza; Live attenuated virus; Vaccines

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; AS03; GENETIC VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNIVERSAL INFLUENZA VACCINE; VIRUS SIALIDASE; VIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENE REARRANGEMENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFECTION PERMISSIVE IMMUNITY; INFLUENZA VIRUS A; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANTIGENIC VARIATION; BIOSYNTHESIS; HUMORAL IMMUNITY; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PANDEMIC; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PANDEMICS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84908241222     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6103809     Document Type: Review

References (133)

1. Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.; Bridges, C.B. The annual impact of seasonal influenza in the us: Measuring disease burden and costs. Vaccine 2007, 25, 5086-5096.
2. Clements, M.L.; Betts, R.F.; Tierney, E.L.; Murphy, B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza a wild-type virus. J. Clin. Microbiol. 1986, 24, 157-160.
3. Westgeest, K.B.; de Graaf, M.; Fourment, M.; Bestebroer, T.M.; van Beek, R.; Spronken, M.I.; de Jong, J.C.; Rimmelzwaan, G.F.; Russell, C.A.; Osterhaus, A.D., et al. Genetic evolution of the neuraminidase of influenza a (h3n2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J. Gen. Virol. 2012, 93, 1996-2007.
4. Hensley, S.E.; Das, S.R.; Bailey, A.L.; Schmidt, L.M.; Hickman, H.D.; Jayaraman, A.; Viswanathan, K.; Raman, R.; Sasisekharan, R.; Bennink, J.R., et al. Hemagglutinin receptor binding avidity drives influenza a virus antigenic drift. Science 2009, 326, 734-736.
5. Garcia-Sastre, A.; Schmolke, M. Avian influenza a h10n8—A virus on the verge? Lancet 2014, 383, 676-677.
6. Butler, D. Portrait of a year-old pandemic. Nature 2010, 464, 1112-1113.
7. Rappuoli, R.; Dormitzer, P.R. Influenza: Options to improve pandemic preparation. Science 2012, 336, 1531-1533.
8. Skowronski, D.M.; Janjua, N.Z.; De Serres, G.; Hottes, T.S.; Dickinson, J.A.; Crowcroft, N.; Kwindt, T.L.; Tang, P.; Charest, H.; Fonseca, K., et al. Effectiveness of as03 adjuvanted pandemic h1n1 vaccine: Case-control evaluation based on sentinel surveillance system in canada, autumn 2009. BMJ 2011, 342, c7297.
9. De Jong, J.C.; Beyer, W.E.; Palache, A.M.; Rimmelzwaan, G.F.; Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic a(h3n2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 2000, 61, 94-99.
10. Skowronski, D.M.; Masaro, C.; Kwindt, T.L.; Mak, A.; Petric, M.; Li, Y.; Sebastian, R.; Chong, M.; Tam, T.; De Serres, G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual a and b vaccine mismatch in canada. Vaccine 2007, 25, 2842-2851.
11. Osterholm, M.T.; Kelley, N.S.; Sommer, A.; Belongia, E.A. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12, 36-44.
12. Belongia, E.A.; Kieke, B.A.; Donahue, J.G.; Greenlee, R.T.; Balish, A.; Foust, A.; Lindstrom, S.; Shay, D.K.; Marshfield Influenza Study Group. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. Lancet Infect. Dis. 2009, 199, 159-167.
13. Palese, P. Making better influenza virus vaccines? Emerg. Infect. Dis. 2006, 12, 61-65.
14. Dormitzer, P.R.; Suphaphiphat, P.; Gibson, D.G.; Wentworth, D.E.; Stockwell, T.B.; Algire, M.A.; Alperovich, N.; Barro, M.; Brown, D.M.; Craig, S., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 2013, 5, 185ra168.
15. Robertson, J.S.; Bootman, J.S.; Newman, R.; Oxford, J.S.; Daniels, R.S.; Webster, R.G.; Schild, G.C. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 1987, 160, 31-37.
16. Szymczakiewicz-Multanowska, A.; Groth, N.; Bugarini, R.; Lattanzi, M.; Casula, D.; Hilbert, A.; Tsai, T.; Podda, A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 2009, 200, 841-848.
17. Ehrlich, H.J.; Muller, M.; Fritsch, S.; Zeitlinger, M.; Berezuk, G.; Low-Baselli, A.; van der Velden, M.V.; Pollabauer, E.M.; Maritsch, F.; Pavlova, B.G., et al. A cell culture (vero)-derived h5n1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 2009, 200, 1113-1118.
18. Lin, Y.P.; Wharton, S.A.; Martin, J.; Skehel, J.J.; Wiley, D.C.; Steinhauer, D.A. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: Selection of hemagglutinin mutants with elevated ph of membrane fusion. Virology 1997, 233, 402-410.
19. Schild, G.C.; Wood, J.M.; Newman, R.W. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull. World Health Organ. 1975, 52, 223-231.
20. Schmeisser, F.; Vodeiko, G.M.; Lugovtsev, V.Y.; Stout, R.R.; Weir, J.P. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010, 28, 2442-2449.
21. Wood, J.M.; Levandowski, R.A. The influenza vaccine licensing process. Vaccine 2003, 21, 1786-1788.
22. Hovden, A.O.; Cox, R.J.; Haaheim, L.R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an igg2a response in balb/c mice. Scand. J. Immunol. 2005, 62, 36-44.
23. Maassab, H.F.; Heilman, C.A.; Herlocher, M.L. Cold-adapted influenza viruses for use as live vaccines for man. Adv. Biotechnol. Processes 1990, 14, 203-242.
24. Basha, S.; Hazenfeld, S.; Brady, R.C.; Subbramanian, R.A. Comparison of antibody and t-cell responses elicited by licensed inactivated-and live-attenuated influenza vaccines against h3n2 hemagglutinin. Hum. Immunol. 2011, 72, 463-469.
25. He, X.S.; Holmes, T.H.; Zhang, C.; Mahmood, K.; Kemble, G.W.; Lewis, D.B.; Dekker, C.L.; Greenberg, H.B.; Arvin, A.M. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 2006, 80, 11756-11766.
26. Soghoian, D.Z.; Streeck, H. Cytolytic cd4(+) t cells in viral immunity. Expert Rev. Vaccines 2010, 9, 1453-1463.
27. McKinstry, K.K.; Strutt, T.M.; Kuang, Y.; Brown, D.M.; Sell, S.; Dutton, R.W.; Swain, S.L. Memory cd4+ t cells protect against influenza through multiple synergizing mechanisms. J. Clin. Investig. 2012, 122, 2847-2856.
28. Barria, M.I.; Garrido, J.L.; Stein, C.; Scher, E.; Ge, Y.; Engel, S.M.; Kraus, T.A.; Banach, D.; Moran, T.M. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J. Infect. Dis. 2013, 207, 115-124.
29. Talon, J.; Salvatore, M.; O’Neill, R.E.; Nakaya, Y.; Zheng, H.; Muster, T.; Garcia-Sastre, A.; Palese, P. Influenza a and b viruses expressing altered ns1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA 2000, 97, 4309-4314.
30. Watanabe, T.; Watanabe, S.; Neumann, G.; Kida, H.; Kawaoka, Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 2002, 76, 767-773.
31. Watanabe, T.; Watanabe, S.; Kida, H.; Kawaoka, Y. Influenza a virus with defective m2 ion channel activity as a live vaccine. Virology 2002, 299, 266-270.
32. Hatta, Y.; Hatta, M.; Bilsel, P.; Neumann, G.; Kawaoka, Y. An m2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (h1n1) 2009 influenza virus. Vaccine 2011, 29, 2308-2312.
33. D’Aoust, M.A.; Lavoie, P.O.; Couture, M.M.; Trepanier, S.; Guay, J.M.; Dargis, M.; Mongrand, S.; Landry, N.; Ward, B.J.; Vezina, L.P. Influenza virus-like particles produced by transient expression in nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 2008, 6, 930-940.
34. Verma, S.; Dimitrova, M.; Munjal, A.; Fontana, J.; Crevar, C.J.; Carter, D.M.; Ross, T.M.; Khurana, S.; Golding, H. Oligomeric recombinant h5 ha1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type h5n1 influenza challenge and controls viral loads better than subunit h5n1 vaccine by eliciting high-affinity antibodies. J. Virol. 2012, 86, 12283-12293.
35. Bosch, B.J.; Bodewes, R.; de Vries, R.P.; Kreijtz, J.H.; Bartelink, W.; van Amerongen, G.; Rimmelzwaan, G.F.; de Haan, C.A.; Osterhaus, A.D.; Rottier, P.J. Recombinant soluble, multimeric ha and na exhibit distinctive types of protection against pandemic swine-origin 2009 a(h1n1) influenza virus infection in ferrets. J. Virol. 2010, 84, 10366-10374.
36. Johansson, B.E. Immunization with influenza a virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999, 17, 2073-2080.
37. Martinet, W.; Saelens, X.; Deroo, T.; Neirynck, S.; Contreras, R.; Min Jou, W.; Fiers, W. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem./FEBS 1997, 247, 332-338.
38. Deroo, T.; Jou, W.M.; Fiers, W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14, 561-569.
39. Treanor, J.J.; Schiff, G.M.; Couch, R.B.; Cate, T.R.; Brady, R.C.; Hay, C.M.; Wolff, M.; She, D.; Cox, M.M. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 2006, 193, 1223-1228.
40. Baxter, R.; Patriarca, P.A.; Ensor, K.; Izikson, R.; Goldenthal, K.L.; Cox, M.M. Evaluation of the safety, reactogenicity and immunogenicity of flublok(r) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011, 29, 2272-2278.
41. Chichester, J.A.; Jones, R.M.; Green, B.J.; Stow, M.; Miao, F.; Moonsammy, G.; Streatfield, S.J.; Yusibov, V. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (hai-05) derived from a/indonesia/05/2005 (h5n1) influenza virus: A phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 2012, 4, 3227-3244.
42. Bright, R.A.; Carter, D.M.; Daniluk, S.; Toapanta, F.R.; Ahmad, A.; Gavrilov, V.; Massare, M.; Pushko, P.; Mytle, N.; Rowe, T., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25, 3871-3878.
43. Fries, L.F.; Smith, G.E.; Glenn, G.M. A recombinant viruslike particle influenza a (h7n9) vaccine. N. Engl. J. Med. 2013, 369, 2564-2566.
44. Landry, N.; Ward, B.J.; Trepanier, S.; Montomoli, E.; Dargis, M.; Lapini, G.; Vezina, L.P. Preclinical and clinical development of plant-made virus-like particle vaccine against avian h5n1 influenza. PLoS One 2010, 5, e15559.
45. Clinicaltrials.Gov. Available online: http://www.clinicaltrials.gov (accessed on 10 July 2014).
46. Kreijtz, J.H.; Suzer, Y.; Bodewes, R.; Schwantes, A.; van Amerongen, G.; Verburgh, R.J.; de Mutsert, G.; van den Brand, J.; van Trierum, S.E.; Kuiken, T., et al. Evaluation of a modified vaccinia virus ankara (mva)-based candidate pandemic influenza a/h1n1 vaccine in the ferret model. J. Gen. Virol. 2010, 91, 2745-2752.
47. Rimmelzwaan, G.F.; Sutter, G. Candidate influenza vaccines based on recombinant modified vaccinia virus ankara. Expert Rev. Vaccines 2009, 8, 447-454.
48. Gurwith, M.; Lock, M.; Taylor, E.M.; Ishioka, G.; Alexander, J.; Mayall, T.; Ervin, J.E.; Greenberg, R.N.; Strout, C.; Treanor, J.J., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for h5n1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis. 2013, 13, 238-250.
49. Hekele, A.; Bertholet, S.; Archer, J.; Gibson, D.G.; Palladino, G.; Brito, L.A.; Otten, G.R.; Brazzoli, M.; Buccato, S.; Bonci, A., et al. Rapidly produced sam[reg] vaccine against h7n9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2013, 2, e52.
50. Lin, J.; Zhang, J.; Dong, X.; Fang, H.; Chen, J.; Su, N.; Gao, Q.; Zhang, Z.; Liu, Y.; Wang, Z., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza a (h5n1) vaccine: A phase i randomised controlled trial. Lancet 2006, 368, 991-997.
51. Leroux-Roels, I.; Borkowski, A.; Vanwolleghem, T.; Drame, M.; Clement, F.; Hons, E.; Devaster, J.M.; Leroux-Roels, G. Antigen sparing and cross-reactive immunity with an adjuvanted rh5n1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007, 370, 580-589.
52. Hatz, C.; Cramer, J.P.; Vertruyen, A.; Schwarz, T.F.; von Sonnenburg, F.; Borkowski, A.; Lattanzi, M.; Hilbert, A.K.; Cioppa, G.D.; Leroux-Roels, G. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived a/h1n1 influenza vaccine in adult and elderly populations. Vaccine 2012, 30, 4820-4827.
53. Khurana, S.; Chearwae, W.; Castellino, F.; Manischewitz, J.; King, L.R.; Honorkiewicz, A.; Rock, M.T.; Edwards, K.M.; del Giudice, G.; Rappuoli, R., et al. Vaccines with mf59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian h5n1 influenza virus. Sci. Transl. Med. 2010, 2, 15ra15.
54. Khurana, S.; Verma, N.; Yewdell, J.W.; Hilbert, A.K.; Castellino, F.; Lattanzi, M.; del Giudice, G.; Rappuoli, R.; Golding, H. Mf59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 2011, 3, 85ra48.
55. Kool, M.; Petrilli, V.; de Smedt, T.; Rolaz, A.; Hammad, H.; van Nimwegen, M.; Bergen, I.M.; Castillo, R.; Lambrecht, B.N.; Tschopp, J. Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the nalp3 inflammasome. J. Immunol. 2008, 181, 3755-3759.
56. Kool, M.; Soullie, T.; van Nimwegen, M.; Willart, M.A.; Muskens, F.; Jung, S.; Hoogsteden, H.C.; Hammad, H.; Lambrecht, B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205, 869-882.
57. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the nalp3 inflammasome. Nature 2006, 440, 237-241.
58. Ng, G.; Sharma, K.; Ward, S.M.; Desrosiers, M.D.; Stephens, L.A.; Schoel, W.M.; Li, T.; Lowell, C.A.; Ling, C.C.; Amrein, M.W., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and syk kinase activation in dendritic cells. Immunity 2008, 29, 807-818.
59. Di Virgilio, F. Purinergic mechanism in the immune system: A signal of danger for dendritic cells. Purinergic Signal. 2005, 1, 205-209.
60. Vono, M.; Taccone, M.; Caccin, P.; Gallotta, M.; Donvito, G.; Falzoni, S.; Palmieri, E.; Pallaoro, M.; Rappuoli, R.; di Virgilio, F., et al. The adjuvant mf59 induces atp release from muscle that potentiates response to vaccination. Proc. Natl. Acad. Sci. USA 2013, 110, 21095-21100.
61. Ellebedy, A.H.; Lupfer, C.; Ghoneim, H.E.; DeBeauchamp, J.; Kanneganti, T.D.; Webby, R.J. Inflammasome-independent role of the apoptosis-associated speck-like protein containing card (asc) in the adjuvant effect of mf59. Proc. Natl. Acad. Sci. USA 2011, 108, 2927-2932.
62. Shah, H.B.; Devera, T.S.; Rampuria, P.; Lang, G.A.; Lang, M.L. Type ii nkt cells facilitate alum-sensing and humoral immunity. J. Leukoc. Biol. 2012, 92, 883-893.
63. Wang, H.B.; Weller, P.F. Pivotal advance: Eosinophils mediate early alum adjuvant-elicited b cell priming and igm production. J. Leukoc. Biol. 2008, 83, 817-821.
64. Jin, B.R.; Kim, S.J.; Lee, J.M.; Kang, S.H.; Han, H.J.; Jang, Y.S.; Seo, G.Y.; Kim, P.H. Alum directly modulates murine b lymphocytes to produce igg1 isotype. Immune Netw. 2013, 13, 10-15.
65. Guven, E.; Duus, K.; Laursen, I.; Hojrup, P.; Houen, G. Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway. PLoS One 2013, 8, e74445.
66. McKee, A.S.; Munks, M.W.; MacLeod, M.K.; Fleenor, C.J.; Van Rooijen, N.; Kappler, J.W.; Marrack, P. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 2009, 183, 4403-4414.
67. Calabro, S.; Tortoli, M.; Baudner, B.C.; Pacitto, A.; Cortese, M.; O’Hagan, D.T.; de Gregorio, E.; Seubert, A.; Wack, A. Vaccine adjuvants alum and mf59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29, 1812-1823.
68. Morel, S.; Didierlaurent, A.; Bourguignon, P.; Delhaye, S.; Baras, B.; Jacob, V.; Planty, C.; Elouahabi, A.; Harvengt, P.; Carlsen, H., et al. Adjuvant system as03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29, 2461-2473.
69. Mosca, F.; Tritto, E.; Muzzi, A.; Monaci, E.; Bagnoli, F.; Iavarone, C.; O'Hagan, D.; Rappuoli, R.; de Gregorio, E. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA 2008, 105, 10501-10506.
70. Seubert, A.; Monaci, E.; Pizza, M.; O'Hagan, D.T.; Wack, A. The adjuvants aluminum hydroxide and mf59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 2008, 180, 5402-5412.
71. Sornasse, T.; Flamand, V.; de Becker, G.; Bazin, H.; Tielemans, F.; Thielemans, K.; Urbain, J.; Leo, O.; Moser, M. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med. 1992, 175, 15-21.
72. Roman, F.; Clement, F.; Dewe, W.; Walravens, K.; Maes, C.; Willekens, J.; de Boever, F.; Hanon, E.; Leroux-Roels, G. Effect on cellular and humoral immune responses of the as03 adjuvant system in an a/h1n1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol.: CVI 2011, 18, 835-843.
73. Moris, P.; van der Most, R.; Leroux-Roels, I.; Clement, F.; Drame, M.; Hanon, E.; Leroux-Roels, G.G.; Van Mechelen, M. H5n1 influenza vaccine formulated with as03 a induces strong cross-reactive and polyfunctional cd4 t-cell responses. J. Clin. Immunol. 2011, 31, 443-454.
74. Tetsutani, K.; Ishii, K.J. Adjuvants in influenza vaccines. Vaccine 2012, 30, 7658-7661.
75. Zurbriggen, R.; Metcalfe, I.C.; Gluck, R.; Viret, J.F.; Moser, C. Nonclinical safety evaluation of escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines 2003, 2, 295-304.
76. Stephenson, I.; Zambon, M.C.; Rudin, A.; Colegate, A.; Podda, A.; Bugarini, R.; Del Giudice, G.; Minutello, A.; Bonnington, S.; Holmgren, J., et al. Phase i evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 2006, 80, 4962-4970.
77. Mutsch, M.; Zhou, W.; Rhodes, P.; Bopp, M.; Chen, R.T.; Linder, T.; Spyr, C.; Steffen, R. Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in switzerland. N. Engl. J. Med. 2004, 350, 896-903.
78. Lewis, D.J.; Huo, Z.; Barnett, S.; Kromann, I.; Giemza, R.; Galiza, E.; Woodrow, M.; Thierry-Carstensen, B.; Andersen, P.; Novicki, D., et al. Transient facial nerve paralysis (bell's palsy) following intranasal delivery of a genetically detoxified mutant of escherichia coli heat labile toxin. PLoS One 2009, 4, e6999.
79. Lu, X.; Clements, J.D.; Katz, J.M. Mutant escherichia coli heat-labile enterotoxin [lt(r192g)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 2002, 20, 1019-1029.
80. McNally, B.; Willette, M.; Ye, F.; Partida-Sanchez, S.; Flano, E. Intranasal administration of dsrna analog poly(i:C) induces interferon-alpha receptor-dependent accumulation of antigen experienced t cells in the airways. PLoS One 2012, 7, e51351.
81. Perez-Giron, J.V.; Belicha-Villanueva, A.; Hassan, E.; Gomez-Medina, S.; Cruz, J.L.; Ludtke, A.; Ruibal, P.; Albrecht, R.A.; Garcia-Sastre, A.; Munoz-Fontela, C. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and t cell immunity. J. Immunol. 2014, 193, 1324-1332.
82. Fang, Y.; Rowe, T.; Leon, A.J.; Banner, D.; Danesh, A.; Xu, L.; Ran, L.; Bosinger, S.E.; Guan, Y.; Chen, H., et al. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J. Virol. 2010, 84, 8369-8388.
83. Quan, F.S.; Ko, E.J.; Kwon, Y.M.; Joo, K.H.; Compans, R.W.; Kang, S.M. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013, 26, 385-395.
84. Ichinohe, T.; Tamura, S.; Kawaguchi, A.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.; Takahashi, H.; Sawa, H., et al. Cross-protection against h5n1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 2007, 196, 1313-1320.
85. Martinez-Gil, L.; Goff, P.H.; Hai, R.; Garcia-Sastre, A.; Shaw, M.L.; Palese, P. A sendai virus-derived RNA agonist of rig-i as a virus vaccine adjuvant. J. Virol. 2013, 87, 1290-1300.
86. Wu, J.; Sun, L.; Chen, X.; Du, F.; Shi, H.; Chen, C.; Chen, Z.J. Cyclic gmp-amp is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339, 826-830.
87. Sun, L.; Wu, J.; Du, F.; Chen, X.; Chen, Z.J. Cyclic gmp-amp synthase is a cytosolic DNA sensor that activates the type i interferon pathway. Science 2013, 339, 786-791.
88. Neirynck, S.; Deroo, T.; Saelens, X.; Vanlandschoot, P.; Jou, W.M.; Fiers, W. A universal influenza a vaccine based on the extracellular domain of the m2 protein. Nat. Med. 1999, 5, 1157-1163.
89. Steel, J.; Lowen, A.C.; Wang, T.T.; Yondola, M.; Gao, Q.; Haye, K.; Garcia-Sastre, A.; Palese, P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1, doi:10.1128/mBio.00018-10.
90. LaMere, M.W.; Lam, H.T.; Moquin, A.; Haynes, L.; Lund, F.E.; Randall, T.D.; Kaminski, D.A. Contributions of antinucleoprotein igg to heterosubtypic immunity against influenza virus. J. Immunol. 2011, 186, 4331-4339.
91. Lamere, M.W.; Moquin, A.; Lee, F.E.; Misra, R.S.; Blair, P.J.; Haynes, L.; Randall, T.D.; Lund, F.E.; Kaminski, D.A. Regulation of antinucleoprotein igg by systemic vaccination and its effect on influenza virus clearance. J. Virol. 2011, 85, 5027-5035.
92. Krammer, F.; Hai, R.; Yondola, M.; Tan, G.S.; Leyva-Grado, V.H.; Ryder, A.B.; Miller, M.S.; Rose, J.K.; Palese, P.; Garcia-Sastre, A., et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 2014, 88, 3432-3442.
93. Krammer, F.; Pica, N.; Hai, R.; Margine, I.; Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 2013, 87, 6542-6550.
94. Fan, J.; Liang, X.; Horton, M.S.; Perry, H.C.; Citron, M.P.; Heidecker, G.J.; Fu, T.M.; Joyce, J.; Przysiecki, C.T.; Keller, P.M., et al. Preclinical study of influenza virus a m2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22, 2993-3003.
95. Sui, J.; Hwang, W.C.; Perez, S.; Wei, G.; Aird, D.; Chen, L.M.; Santelli, E.; Stec, B.; Cadwell, G.; Ali, M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses. Nat. Struct. Mol. Biol. 2009, 16, 265-273.
96. Wrammert, J.; Koutsonanos, D.; Li, G.M.; Edupuganti, S.; Sui, J.; Morrissey, M.; McCausland, M.; Skountzou, I.; Hornig, M.; Lipkin, W.I., et al. Broadly cross-reactive antibodies dominate the human b cell response against 2009 pandemic h1n1 influenza virus infection. J. Exp. Med. 2011, 208, 181-193.
97. Krammer, F.; Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 2013, 3, 521-530.
98. Corti, D.; Voss, J.; Gamblin, S.J.; Codoni, G.; Macagno, A.; Jarrossay, D.; Vachieri, S.G.; Pinna, D.; Minola, A.; Vanzetta, F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins. Science 2011, 333, 850-856.
99. Ekiert, D.C.; Kashyap, A.K.; Steel, J.; Rubrum, A.; Bhabha, G.; Khayat, R.; Lee, J.H.; Dillon, M.A.; O’Neil, R.E.; Faynboym, A.M., et al. Cross-neutralization of influenza a viruses mediated by a single antibody loop. Nature 2012, 489, 526-532.
100. Sui, J.; Sheehan, J.; Hwang, W.C.; Bankston, L.A.; Burchett, S.K.; Huang, C.Y.; Liddington, R.C.; Beigel, J.H.; Marasco, W.A. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza a antibodies. Clin. Infect. Dis.2011, 52, 1003-1009.
101. Corti, D.; Suguitan, A.L., Jr.; Pinna, D.; Silacci, C.; Fernandez-Rodriguez, B.M.; Vanzetta, F.; Santos, C.; Luke, C.J.; Torres-Velez, F.J.; Temperton, N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 2010, 120, 1663-1673.
102. Avnir, Y.; Tallarico, A.S.; Zhu, Q.; Bennett, A.S.; Connelly, G.; Sheehan, J.; Sui, J.; Fahmy, A.; Huang, C.Y.; Cadwell, G., et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza a viruses. PLoS Pathog. 2014, 10, e1004103.
103. Krause, J.C.; Tumpey, T.M.; Huffman, C.J.; McGraw, P.A.; Pearce, M.B.; Tsibane, T.; Hai, R.; Basler, C.F.; Crowe, J.E., Jr. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza a (h1n1) viruses. J. Virol. 2010, 84, 3127-3130.
104. Ekiert, D.C.; Friesen, R.H.; Bhabha, G.; Kwaks, T.; Jongeneelen, M.; Yu, W.; Ophorst, C.; Cox, F.; Korse, H.J.; Brandenburg, B., et al. A highly conserved neutralizing epitope on group 2 influenza a viruses. Science 2011, 333, 843-850.
105. Throsby, M.; van den Brink, E.; Jongeneelen, M.; Poon, L.L.; Alard, P.; Cornelissen, L.; Bakker, A.; Cox, F.; van Deventer, E.; Guan, Y., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against h5n1 and h1n1 recovered from human igm+ memory b cells. PLoS One 2008, 3, e3942.
106. Corti, D.; Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013, 31, 705-742.
107. El Bakkouri, K.; Descamps, F.; De Filette, M.; Smet, A.; Festjens, E.; Birkett, A.; Van Rooijen, N.; Verbeek, S.; Fiers, W.; Saelens, X. Universal vaccine based on ectodomain of matrix protein 2 of influenza a: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186, 1022-1031.
108. Song, J.M.; Van Rooijen, N.; Bozja, J.; Compans, R.W.; Kang, S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza a virus. Proc. Natl. Acad. Sci. USA 2011, 108, 757-761.
109. Jegerlehner, A.; Schmitz, N.; Storni, T.; Bachmann, M.F. Influenza a vaccine based on the extracellular domain of m2: Weak protection mediated via antibody-dependent nk cell activity. J. Immunol. 2004, 172, 5598-5605.
110. Schmitz, N.; Beerli, R.R.; Bauer, M.; Jegerlehner, A.; Dietmeier, K.; Maudrich, M.; Pumpens, P.; Saudan, P.; Bachmann, M.F. Universal vaccine against influenza virus: Linking tlr signaling to anti-viral protection. Eur. J. Immunol. 2012, 42, 863-869.
111. DiLillo, D.J.; Tan, G.S.; Palese, P.; Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require fcgammar interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20, 143-151.
112. Schotsaert, M.; Saelens, X.; Leroux-Roels, G. Influenza vaccines: T-cell responses deserve more attention. Expert Rev. Vaccines 2012, 11, 949-962.
113. Wilkinson, T.M.; Li, C.K.; Chui, C.S.; Huang, A.K.; Perkins, M.; Liebner, J.C.; Lambkin-Williams, R.; Gilbert, A.; Oxford, J.; Nicholas, B., et al. Preexisting influenza-specific cd4+ t cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012, 18, 274-280.
114. McMichael, A.J.; Gotch, F.M.; Noble, G.R.; Beare, P.A. Cytotoxic t-cell immunity to influenza. N. Engl. J. Med. 1983, 309, 13-17.
115. Sridhar, S.; Begom, S.; Bermingham, A.; Hoschler, K.; Adamson, W.; Carman, W.; Bean, T.; Barclay, W.; Deeks, J.J.; Lalvani, A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 2013, 19, 1305-1312.
116. Galli, G.; Medini, D.; Borgogni, E.; Zedda, L.; Bardelli, M.; Malzone, C.; Nuti, S.; Tavarini, S.; Sammicheli, C.; Hilbert, A.K., et al. Adjuvanted h5n1 vaccine induces early cd4+ t cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 2009, 106, 3877-3882.
117. Rimmelzwaan, G.F.; Nieuwkoop, N.; Brandenburg, A.; Sutter, G.; Beyer, W.E.; Maher, D.; Bates, J.; Osterhaus, A.D. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza iscom vaccines and conventional vaccines. Vaccine 2000, 19, 1180-1187.
118. Hoft, D.F.; Babusis, E.; Worku, S.; Spencer, C.T.; Lottenbach, K.; Truscott, S.M.; Abate, G.; Sakala, I.G.; Edwards, K.M.; Creech, C.B., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse t-cell responses in young children. J. Infect. Dis. 2012, 204, 845-853.
119. Berthoud, T.K.; Hamill, M.; Lillie, P.J.; Hwenda, L.; Collins, K.A.; Ewer, K.J.; Milicic, A.; Poyntz, H.C.; Lambe, T.; Fletcher, H.A., et al. Potent cd8+ t-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, mva-np+m1. Clin. Infect. Dis. 2011, 52, 1-7.
120. Bodewes, R.; Fraaij, P.L.; Geelhoed-Mieras, M.M.; van Baalen, C.A.; Tiddens, H.A.; van Rossum, A.M.; van der Klis, F.R.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Annual vaccination against influenza virus hampers development of virus-specific cd8(+) t cell immunity in children. J. Virol. 2011, 85, 11995-12000.
121. Bodewes, R.; Kreijtz, J.H.; Rimmelzwaan, G.F. Yearly influenza vaccinations: A double-edged sword? Lancet Infect. Dis. 2009, 9, 784-788.
122. Bodewes, R.; Kreijtz, J.H.; Baas, C.; Geelhoed-Mieras, M.M.; de Mutsert, G.; van Amerongen, G.; van den Brand, J.M.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination against human influenza a/h3n2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza a/h5n1 virus. PLoS One 2009, 4, e5538.
123. Bodewes, R.; Kreijtz, J.H.; Geelhoed-Mieras, M.M.; van Amerongen, G.; Verburgh, R.J.; van Trierum, S.E.; Kuiken, T.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination against seasonal influenza a/h3n2 virus reduces the induction of heterosubtypic immunity against influenza a/h5n1 virus infection in ferrets. J. Virol. 2011, 85, 2695-2702.
124. Schotsaert, M.; Ysenbaert, T.; Neyt, K.; Ibanez, L.I.; Bogaert, P.; Schepens, B.; Lambrecht, B.N.; Fiers, W.; Saelens, X. Natural and long-lasting cellular immune responses against influenza in the m2e-immune host. Mucosal Immunol. 2013, 6, 276-287.
125. Ferguson, N.M.; Anderson, R.M. Predicting evolutionary change in the influenza a virus. Nat. Med. 2002, 8, 562-563.
126. Schulman, J.L.; Khakpour, M.; Kilbourne, E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 1968, 2, 778-786.
127. Rockman, S.; Brown, L.E.; Barr, I.G.; Gilbertson, B.; Lowther, S.; Kachurin, A.; Kachurina, O.; Klippel, J.; Bodle, J.; Pearse, M., et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal h5n1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 2013, 87, 3053-3061.
128. Easterbrook, J.D.; Schwartzman, L.M.; Gao, J.; Kash, J.C.; Morens, D.M.; Couzens, L.; Wan, H.; Eichelberger, M.C.; Taubenberger, J.K. Protection against a lethal h5n1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic h1n1 neuraminidase in mice. Virology 2012, 432, 39-44.
129. Wan, H.; Gao, J.; Xu, K.; Chen, H.; Couzens, L.K.; Rivers, K.H.; Easterbrook, J.D.; Yang, K.; Zhong, L.; Rajabi, M., et al. Molecular basis for broad neuraminidase immunity: Conserved epitopes in seasonal and pandemic h1n1 as well as h5n1 influenza viruses. J. Virol. 2013, 87, 9290-9300.
130. Quan, F.S.; Kim, M.C.; Lee, B.J.; Song, J.M.; Compans, R.W.; Kang, S.M. Influenza m1 vlps containing neuraminidase induce heterosubtypic cross-protection. Virology 2012, 430, 127-135.
131. Caskey, M.; Lefebvre, F.; Filali-Mouhim, A.; Cameron, M.J.; Goulet, J.P.; Haddad, E.K.; Breton, G.; Trumpfheller, C.; Pollak, S.; Shimeliovich, I., et al. Synthetic double-stranded rna induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208, 2357-2366.
132. Querec, T.D.; Akondy, R.S.; Lee, E.K.; Cao, W.; Nakaya, H.I.; Teuwen, D.; Pirani, A.; Gernert, K.; Deng, J.; Marzolf, B., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009, 10, 116-125.
133. Nakaya, H.I.; Wrammert, J.; Lee, E.K.; Racioppi, L.; Marie-Kunze, S.; Haining, W.N.; Means, A.R.; Kasturi, S.P.; Khan, N.; Li, G.M., et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 2011, 12, 786-795.